Nanobiotix (NASDAQ:NBTX) Earns Buy Rating from Analysts at Guggenheim

Guggenheim started coverage on shares of Nanobiotix (NASDAQ:NBTX) in a research note published on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $64.00 price objective on the stock.

A number of other analysts have also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Leerink Partners increased their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Nanobiotix presently has an average rating of “Moderate Buy” and an average price target of $46.67.

Nanobiotix Price Performance

Nanobiotix stock opened at $35.88 on Tuesday. Nanobiotix has a one year low of $10.58 and a one year high of $57.14. The company’s fifty day moving average price is $39.36 and its two-hundred day moving average price is $37.35.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.